GeoVax Labs (GOVX) Price & Analysis

Compare

893 Followers

GOVX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.43 - $11.18

Previous CloseN/A

Volume281.82K

Average Volume (3M)2.25M

Market Cap

$18.49M

Enterprise Value$10.20M

Total Cash (Recent Filing)$3.09M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.87

Next Earnings

Nov 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding25,359,592

10 Day Avg. Volume1,279,258

30 Day Avg. Volume2,247,211

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.55

Enterprise Value/Revenue1.93

Enterprise Value/Gross Profit1.94

Enterprise Value/Ebitda-0.41

Forecast

1Y Price Target

$10.83

Price Target Upside1383.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical StudiesAdditional data announcements from clinical studies with 04S1 could be positive catalysts through 2025.

Comparative AnalysisDSMB Review Suggests GEO-CM04S1 May Be Superior to mRNA Vaccine.

Vaccine DevelopmentGEO-CM04S1 booster studies to continue, with early clinical studies showing the vaccine induces durable neutralizing antibody and T-cell-based immunity against current and future variants of SARS-CoV-2.

Bears Say

Contract TerminationTermination of the contract will not have a long-term material effect.

Project TerminationGeoVax Labs announced it received written notification from Advanced Technology International directing GeoVax to stop work on all efforts with respect to a Rapid Response Partnership Vehicle project.

GeoVax Labs News

HHS mRNA vaccine decision bodes well for GeoVax Labs, says Roth Capital

Roth Capital notes that the U.S. Department of Health and Human Services terminated almost $500M in BARDA-funded mRNA...

22h ago

GOVX

Meet GeoVax Labs: Fly exclusive interview with CEO David Dodd

In an exclusive interview, GeoVax Labs’ (GOVX) CEO David Dodd met with The Fly to discuss the company,...

15d ago

GOVX

GeoVax Labs CEO says current political climate ‘highly favorable’

14:01 EDT GeoVax Labs (GOVX) CEO says current political climate ‘highly favorable’ Published first on TheFly – the...

15d ago

GOVX

GeoVax CEO sees EMA decision as significant regulatory milestone

14:01 EDT GeoVax CEO sees EMA decision as significant regulatory milestone Published first on TheFly – the ultimate...

15d ago

GOVX

GeoVax sees Gedeptin technology as potentially applicable to any solid tumor

14:01 EDT GeoVax sees Gedeptin technology as potentially applicable to any solid tumor Published first on TheFly –...

15d ago

GOVX

GeoVax Labs Earnings Call: Mixed Results and Future Prospects

Geovax Labs, Inc. (($GOVX)) has held its Q2 earnings call. Read on for the main highlights of the...

3d ago

GOVX

GeoVax Labs Receives Nasdaq Deficiency Letter

GeoVax Labs ( ($GOVX) ) has provided an announcement. On July 31, 2025, GeoVax Labs received a deficiency...

7d ago

GOVX

GeoVax Labs Announces $6 Million Public Offering

GeoVax Labs ( ($GOVX) ) has provided an announcement. On July 1, 2025, GeoVax Labs, Inc. announced a...

1M ago

GOVX

GeoVax’s EMA guidance provides clear pathway, says Alliance Global Partners

Alliance Global Partners reiterates a Buy rating and $8.50 price target on shares of GeoVax Labs (GOVX), telling...

2M ago

GOVX

Closing Bell Movers: Solar stocks fall on tax credit threat

In the opening hour of the evening session, U.S. equity futures are down modestly – S&P 500 and...

2M ago

LEN

RDW

GeoVax Labs files to sell 6.15M common units

Each common unit consists of one share of common stock and two common warrants to purchase one share...

2M ago

GOVX

GeoVax Labs receives favorable European regulatory guidance supporting GEO-MVA

GeoVax Labs (GOVX) announced that it has received positive Scientific Advice, SA, from the European Medicines Agency, EMA,...

2M ago

GOVX

GeoVax Labs Holds Annual Stockholders Meeting June 2025

GeoVax Labs ( ($GOVX) ) has provided an announcement. GeoVax Labs held its annual meeting of stockholders on...

2M ago

GOVX

GeoVax Labs Earnings Call: Mixed Sentiment and Future Prospects

Geovax Labs, Inc. (($GOVX)) has held its Q1 earnings call. Read on for the main highlights of the...

3M ago

GOVX

GOVX FAQ

What was Geovax Labs, Inc.’s price range in the past 12 months?

Geovax Labs, Inc. lowest stock price was $0.43 and its highest was $11.18 in the past 12 months.

What is Geovax Labs, Inc.’s market cap?

Geovax Labs, Inc.’s market cap is $18.49M.

When is Geovax Labs, Inc.’s upcoming earnings report date?

Geovax Labs, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.

How were Geovax Labs, Inc.’s earnings last quarter?

Geovax Labs, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.347 by -$0.003.

Is Geovax Labs, Inc. overvalued?

According to Wall Street analysts Geovax Labs, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Geovax Labs, Inc. pay dividends?

Geovax Labs, Inc. does not currently pay dividends.

What is Geovax Labs, Inc.’s EPS estimate?

Geovax Labs, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Geovax Labs, Inc. have?

Geovax Labs, Inc. has 25,359,592 shares outstanding.

What happened to Geovax Labs, Inc.’s price movement after its last earnings report?

Geovax Labs, Inc. reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.347. Following the earnings report the stock price went down -9.589%.

Which hedge fund is a major shareholder of Geovax Labs, Inc.?

Currently, no hedge funds are holding shares in GOVX

Company Description

Geovax Labs, Inc.

GeoVax Labs (GOVX) is a biotechnology company specializing in developing human vaccines. The company's primary focus is on creating vaccines for infectious diseases, cancer immunotherapy, and other novel treatments by utilizing their innovative MVA-VLP vaccine platform. GeoVax leverages its expertise in vaccine development to address global health challenges, aiming to provide solutions for diseases such as HIV, Zika, Lassa fever, Ebola, and COVID-19.

GeoVax Labs (GOVX) Earnings & Revenues

Historic Earnings Reports

GOVX Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture. Significant achievements included the EMA's expedited path for GEO-MVA, increased revenues, and progress in vaccine development. However, these were offset by the termination of the BARDA contract, increased expenses, and continued net losses, leading to balanced highlights and lowlights.View all GOVX earnings summaries

GOVX Stock 12 Month Forecast

Average Price Target

$10.83

▲(1383.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","7":"$7","11":"$11","15":"$15","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3,7,11,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,1.7415384615384615,2.763076923076923,3.7846153846153845,4.806153846153846,5.827692307692307,6.849230769230769,7.8707692307692305,8.892307692307693,9.913846153846155,10.935384615384615,11.956923076923077,12.97846153846154,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,1.4976923076923077,2.275384615384615,3.0530769230769232,3.8307692307692305,4.608461538461539,5.386153846153846,6.163846153846154,6.941538461538461,7.7192307692307685,8.496923076923077,9.274615384615386,10.052307692307693,{"y":10.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,1.3184615384615386,1.916923076923077,2.5153846153846153,3.113846153846154,3.712307692307692,4.310769230769231,4.909230769230769,5.507692307692308,6.1061538461538465,6.704615384615384,7.303076923076923,7.901538461538462,{"y":8.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.82,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >